This article is more than 5 years old. Information may no longer be current.

VIDEO: TRC101 well-tolerated in treatment of metabolic acidosis in patients with chronic kidney disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At ASN Kidney Week, Donald E. Wesson, MD, MBA, professor of medicine at Texas A&M Health Sciences Center, College of Medicine, spoke about the results of a phase 3 trial of TRC101, a non-absorbed, hydrochloric acid binder.

In the multicenter, randomized, double-blind, placebo-controlled trial, patients with chronic kidney disease received treatment with TRC101 for metabolic acidosis. Wesson said TRC101 effectively and safely treated metabolic acidosis and patients showed improved self-reported physical functioning.

“We have a very effective, well-tolerated and innovative way by which we can treat metabolic acidosis,” he said. “Were this drug to show these sustained results over the longer trial that is now being planned, it eventually has good chances of being approved and in the hands of nephrologists and other physicians in the near future to treat this very common and very harmful, but as of right now, undertreated complication of chronic kidney disease.”

Reference: Wesson DE, et al. Abstract: TH-PO1154. Presented at: ASN Kidney Week; Oct. 23-28, 2018; San Diego.